July 20 , 2012 - The parties filed a stipulation withdrawing the appeal. The U.S. Court of Appeals for the Second Circuit granted the stipulation.
May 24, 2012 - The plaintiffs filed a notice of appeal.

April 26, 2012 - The court granted the defendants' motions to dismiss and closed the case.

February 22, 2012 - The court denied the lead plaintiff motion without prejudice.

November 14, 2011 - Another defendant filed a motion to dismiss.

October 12, 2011 - The court denied the defendants' motions to dismiss.

October 6, 2011 - Defendants filed motions to dismiss.

September 19, 2011 - The plaintiffs filed a second amended complaint.

March 28, 2011 - Defendants filed motions to dismiss.

March 22, 2011 - Lead plaintiff motion was filed.

March 2, 2011 - The plaintiffs filed an amended complaint.

January 4, 2011 - An investor in shares of Human Genome Sciences (NASDAQ: HGSI) filed a lawsuit in the U.S. District Court for the District of Connecticut against FrontPoint Partners LLC and others over alleged insider trading.

Human Genome Sciences’ Total revenue increase by 10 times between 2006 and 2009. While Human Genome Sciences reported a 12 months Total Revenue of $25.75million in 2006 in 2009 it reported a Total Revenue of $275.75million. For the first three quarters in 2010 Human Genome Sciences reported a combined 9months Total Revenue of $136.08million. Its Net income went from a substantial Net Loss in 2006 of $264.09million to a Net Income of $5.66million in 2009.
According to the class action complaint the plaintiff alleges on behalf of all persons and entities that purchased shares of Human Genome Sciences from December 7, 2007 through January 22, 2008 that six healthcare-related hedge funds (the Hedge Funds ) managed by FrontPoint Partners LLC sold 6,164,500 shares of HGSI common stock while their portfolio manager, Joseph F. Chip Skowron, was in possession of material negative non-public information concerning HGSI's clinical trial for the drug Albumin Interferon Alfa 2-a.

FrontPoint Partners LLC has liquidated the hedge fund defendants and distributed most of their assets to the investors in those hedge funds. A law firm is currently seeking a temporary restraining order and a preliminary injunction to prevent further distribution of monies from the FrontPoint hedge funds

The plaintiff alleges that Joseph F. Skowron's information came from Yves Benhamou, M.D., one of five members of a Steering Committee overseeing the Albumin Interferon Alfa 2-a trial. On January 23, 2008, Human Genome Sciences publicly disclosed the negative information regarding the Albumin Interferon Alfa 2-a trial, causing the price of Human Genome Sciences stock to fall $4.40 per share to $5.62 per share, a 44% decline. Accordingly, the Hedge Funds avoided just over $30 million in losses as a result of their unlawful sales of HGSI stock while in possession of material adverse information regarding HGSI, so the lawsuit.

Then HGSI shares traded during December 07 over $11 per share and fell until January 08 to under $6 per share. HGSI shares traded during the first half of 09 as low as $0.71 per share and increased through the end of 09 to as much as $30.58 per share. Recently shares of Human Genome Sciences (HGSI) traded at $26.85 per share.